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Abstract
Poisoning results from the ingestion of or contact with harmful substances including overdose or incorrect use of any drug or medication. 
Decontamination measures prevent the absorption of the substance from the gastrointestinal tract to minimize systemic effects. Activated 
charcoal is the intervention most frequently used in the initial management of patients with acute intoxications. The use of activated charcoal 
has decreased over time, but there may be a subgroup of patients who would benefit from its use. In this review we describe the epidemiology 
of intoxications, the composition and pharmacology of activated charcoal, indications and dosing for use of single dose and multiple doses of 
charcoal, contraindications, complications and a summary for recommended use of this measure based on published studies. 
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Introduction
The National Center for Health Statistics (NCHS) defines a poiso-
ning episode as “the event resulting from ingestion of or con-
tact with harmful substances including overdose or incorrect 
use of any drug or medication” (Available from: http://www.
cdc.gov/nchs/nhis/injury_poisoning/ip_glossary.htm, updated 
January 25, 2010, cited September 10, 2016). Acute poisonings 
are caused by ingestion of different toxic substances that are 
found in products we use at home, industry and the pharma-
ceutical sector, these substances can be acids, bases, salts, 
heavy metals, iodine tincture and others numerous chemicals. 
Poisonings impact the patient’s health through either local or 
systemic effects. Local effects depend on the substance’s spe-
cific chemical characteristics and structure.1,2 Systemic effects 
are obtained when the substance is absorbed and reaches 
the bloodstream to be subsequently distributed to tissues.1,2 
The systemic effects can be avoided by performing an inter-
vention to prevent the absorption of the substance from the 
gastrointestinal tract.1,2 There are several interventions have 
been designed to prevent the absorption of toxic substances, 
including gastric lavage or administration of an adsorbent, 
which are called techniques of gastrointestinal decontamina-
tion.2,3 Of these, activated charcoal (AC) is the most frequently 
used gastrointestinal decontamination method in the initial 
management of patients with acute intoxications.1,2,4 Despite 
intoxications being among the first causes of accidental death, 
medical toxicology remains a small subspecialty of emergen-
cy medicine and knowledge of these topics among physicians 
in general can be limited.5 Here we present a review of the 
use of activated charcoal for acute poisonings with a practical 
approach. The MEDLINE, EMBASE and Current Contents/Science 
Edition databases were searched mainly with the MeSH terms 
"Charcoal” and free text “Activated Charcoal”, “gastrointestinal 
decontamination” and relevant articles selected based on the 
title and abstract. Articles were also selected from the referen-
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ces cited in the articles reviewed.
Epidemiology
A recent systematic review of data from the World Health Or-
ganization, PubMed and Google reports that unintentional in-
gestion, inhalation or contact with chemicals caused 346,000 
deaths (7,447,000 disability-adjusted life years) from acute poi-
sonings in 2004, of which approximately 71% were estimated 
to be preventable.6 National epidemiological sources such as 
the United States National Center for Health Statistics reported 
that poisoning was the second leading cause of injury-related 
death in 2004 and the rate was higher than at any time since 
1968.7 By 2008 poisoning became the first cause of accidental 
death in the US.5 Data from the US National Vital Statistics Sys-
tem mortality report that deaths from unintentional poisoning 
increased at a rate of 62.5%, with 95% of these being secondary 
to drug use, while poisoning by suicide increased by a rate of 
10.8%.8 The American Association of Poison Control Centers' 
(APCC) National Poison Data System (NPDS) report that in 2014 
there were 2,165,142 human exposures reported to the poi-
son control centers, most of which were unintentional (79.4%) 
and secondary to single-substance exposures. The main intoxi-
cation agents in order of frequency were analgesics (11.3%), 
cosmetics/personal care products (7.7%), household cleaning 
substances (7.7%), sedatives/hypnotics/antipsychotics (5.9%), 
and antidepressants (4.4%); which was equivalent to 51.9% 
being secondary to non-pharmaceuticals and 48.1% to phar-
maceuticals. Ingestion was the main route of exposure (83.7%). 
The rate of single-substance exposure-related fatal cases was 
620 for pharmaceuticals compared with 262 for non-pharma-
ceuticals (70.3% and 29.7% respectively), illustrating how expo-
sures to pharmaceuticals had more severe outcomes. Children 
younger than 6 years accounted for approximately half of all 
human exposures (47.7%). Most toxic exposures occurred at a 
residence (93.5%), followed by the workplace (1.7%), schools 
(1.3%), health care facilities (0.3%), and restaurants or food 
The International Journal of Medical Students Int J Med Students   •   2017  |  Jan-Apr  |  Vol  5  |  Issue 146
IJMS
International Journal of 
Medical Students Review
Bonilla-Velez J, et al. The Use of Activated Charcoal for Acute Poisonings
Amitriptyline
Carbamazepine
Cyclosporine
Dapsone
Dextropropoxyphene
Digitoxin
Digoxin
Disopyramide
Nadolol
Phenobarbital
Phenylbutazone
Phenytoin
Piroxicam
Propoxyfene
Quinine
Sotalol
Theophylline
Table 1. Substances in which Clearance is Increased by Multiple 
Doses of Activated Charcoal
services (0.2%). Of all the intoxications reported there were 
8.01% that had a clinically moderate or major effect or resulted 
in death. The use of activated charcoal has declined over time 
and is currently listed as the fourth most common method of 
decontamination used, after Dilute/irrigate/wash, Food/snack, 
or Fresh air (46,030 compared to 796,400, 179,470, and 68,722 
cases respectively) but it remains to be the first gastrointesti-
nal decontamination intervention employed.4 
Likewise, the Central Information Security of Chemicals of Co-
lombia reported that in 2011 there were 4442 calls for advice 
on toxicological emergencies, where 46.4% were secondary to 
voluntary intoxication followed by accidental poisonings, and 
occupational exposure corresponded to 7.2% corresponding to 
1.76 daily emergencies due to exposure to substances in the 
workplace, mainly pesticides (CISPROQUIM. Colombian Coun-
cil of Security: Annual Report on Emergencies 2009. Available 
from: http://ccs.org.co/interna_cispro.php?idnoticia=142&opca-
cordeon=8, updated 2016 Jul 7; cited 2016 Jul 7). As illustrated, 
acute intoxications remain an important cause of morbidity and 
mortality that vary by location, therefore understanding and 
applying these concepts in relation to gastrointestinal decon-
tamination can have a large impact on the outcome for these 
patients.
Composition and Mechanism of Action of Ac-
tivated Charcoal
Activated Charcoal
Activated charcoal is a mixture of particles which are insoluble 
and are produced by heating pulverized carbonaceous substan-
ces (for example sawdust, peat, or coconut shells) to extreme 
temperatures (600-900°C). Subsequently this substance is sub-
mitted to the “activation phase” by using steam to erode the 
internal surfaces of the product, this results in an increase of 
its adsorptive surface area.1,2 The average surface area for ac-
tivated charcoal is 800-1,200 m2/g.1 “Superactivated” charcoal 
may have a surface area of 2,800-3,500 m2/g and can adsorb 
greater quantities of the substance.1.9
Mechanism of Action
Activated charcoal acts like an agent that adsorbs substances 
localized in the gastrointestinal tract and retains them within 
the charcoal, thus minimizing the absorption into the bloods-
tream and reducing or preventing systemic toxicity.1,2,10,11 The 
terms adsorption and absorption are therefore used distincti-
vely to describe each process. To ensure contact of the charcoal 
with the toxic agent prior to absorption by the mucosa it must 
be administered as soon as possible. Any delay may decrease 
its effectiveness.1,2 
The absorptive surface of activated charcoal contains several 
chemical forms, such as carbonyl and hydroxyl groups, which 
adsorbs toxic substances with different affinities.1 Studies in 
vitro have indicated that several factors can influence its ad-
sorptive capacity, such as temperature, pore size, particle size, 
surface area, solubility and toxic ionization stage, the pH, the 
presence of inorganic salts, and the gastric contents; most of 
which cannot be controlled or modified when providing clinical 
care to the intoxicated patient.12 
The effectiveness of activated charcoal depends on multiple 
factors: the longer time elapsed from ingestion to adminis-
tration reduces its efficacy, as well as presence of food in the 
gastrointestinal tract, inherent chemical composition and cha-
racteristics of the substance itself (for example lipid solubility) 
and the presence of other substances that decrease intestinal 
transit time. In addition, effectiveness can also be altered due 
to the phenomenon of desorption, which can occur when a 
complex of activated charcoal and a toxic weak acid change 
from a highly acidic pH in the stomach to an alkaline pH in the 
small intestine that leads to release of the substance from the 
charcoal and thus may lead to some absorption of substance 
into the body. Some suggest that this phenomenon rarely has 
clinical significance.1,12
Furthermore, volunteer studies demonstrate that the maximum 
reduction in the absorption of toxic substances was obtained 
when active charcoal was administered within the first hour of 
toxic intake.1,13 Some studies have shown that activated char-
coal can be effective up to 4 hours after ingestion but efficacy 
decreases over time.13,14 Other studies have shown inconsistent 
results on the benefit of its administration two hours after the 
ingestion of the toxic substance.1,11 Therefore there is a poten-
tial benefit of administration of activated charcoal if administe-
red after 1 hour from ingestion. In addition, due to the adsorp-
tive effect and prevention of absorption of toxic substances 
into the bloodstream, some authors have suggested that AC 
may enhance the elimination of substances.12-14 This will be 
further discussed in section 4.3.
Indications 
Use of gastrointestinal decontamination measures in the emer-
gency department continues to be a controversial topic in the 
toxicology literature.14 The formal recommendation from the 
American Academy of Clinical Toxicology and the European As-
sociation of Poisons Centres and Clinical Toxicologists in their 
position paper in 1997 recommended its use only within an 
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hour of the intoxication and this recommendation was main-
tained in their subsequent 2005 update.1,15 There has not been 
much literature published in this topic over the past 2 decades 
and therefore under the paradigm of evidence-based medicine 
there is limited data to support the use of activated charcoal, 
and some authors have suggested that combined with the low 
mortality observed in intoxicated patients administration may 
not be warranted.14 However, there could be a subgroup of 
patients who would benefit from activated charcoal and efforts 
have been made to offer recommendations for patient selec-
tion which will be described below. 
The two well designed clinical trials evaluating the benefit of 
activated charcoal had significant limitations. Cooper et al. ran-
domized all patients over 16 who presented within 12 hours of 
an intoxication to receiving activated charcoal or no decontami-
nation. The study was performed between July 1999 and Octo-
ber 2000 on sequential patients who presented to the Emergen-
cy Department at The Canberra Hospital in Australia. Patients 
were randomized to activated charcoal (AC) or no gastro-intes-
tinal decontamination as indicated by the sealed sequentially 
numbered envelope contents. The trial recruited 327 patients 
over 16 months. The most common  substances  ingested  were 
benzodiazepines,  acetaminophen  and  selective serotonin 
reuptake  inhibitor   antidepressants. More than 80% of pa-
tients presented within 4 hours following ingestion. There were 
no differences between AC and no decontamination in terms 
of length of stay (AC 6.75 h, IQR 4–14 vs. controls 5.5 h, IQR 
3–12; p 0.11) or secondary outcomes including vomiting, mor-
tality and intensive care admission.16 Some of the limitations 
on this study is that it included patients who were unlikely to 
develop significant toxicity and would have therefore had good 
outcomes irrespective of AC and it excluded seven patients 
with severe toxicity.14 The second study by Eddleston et al. who 
conducted a randomized controlled trial comparing outcomes 
for patients treated with single or multiple doses of activated 
charcoal (SDAC and MDAC respectively) to no charcoal (no AC). 
They report no reduction in risk of death from use of multiple 
dose activated charcoal, with odds ratio of MDAC vs no AC 
0.93 (CI 95% 0.69–1.25), SDAC vs no AC 1.05 (CI 95% 0.79–1.40), 
MDAC vs SDAC 0.89 (CI 95% 0.66–1.19).17 Unfortunately this 
study mainly included patients with intoxications from pesti-
cides and oleander so it is difficult to apply these findings to 
patients who have had intoxications from prescription drugs.14 
No studies have been performed on selected patients based on 
strict criteria to attempt to identify the subgroup of patients 
who would benefit from these interventions. A summary of 
important studies has been performed by other authors and is 
available for review.14,18,19 
Single Dose of Activated Charcoal
There are no absolute indications for the administration of 
activated charcoal.2 Universal routine administration is not 
recommended in the poisoned patient.2,10,11,14,16,17,20 Activated 
charcoal should be administered in patients who have a his-
tory of ingestion of a potentially toxic amount of a substance 
and present to an emergency department within the first hour 
of the event.1,10,11 However, the benefit of its administration on 
patients out of this time-frame cannot be excluded.1 The natio-
nal guideline for acetaminophen overdose in Australia and New 
Zealand recommend use of AC up to 2 hours after ingestion.21
Greene et al,2 suggest that activated charcoal should be admi-
nistered when all the following criteria are met:
1. Intake of a potentially toxic substance.
2. No contraindications for its use.
3. The ingested substance is susceptible to be ad-
sorbed by activated charcoal.
4. There is high probability that the substance is still in 
the gastrointestinal tract at the time of administration.
5. The patient is alert and can protect its airway, or has 
been intubated prior to its administration.
6. The gastrointestinal tract is anatomically and func-
tionally intact.
7. There are no alternative therapies that are safer and/
or more effective.
Bailey et al. recommends the implementation of the "Triangle 
of gastrointestinal decontamination" to determine whether or 
not to perform gastrointestinal decontamination.22 The triangle 
can be used to evaluate the risk versus benefit of this therapy 
and should be applied considering all the variables at the same 
time and not consecutively.3,22
• Will the intake of this substance have significant 
effects?
• Can gastrointestinal decontamination change the 
outcome for this patient?
• Can the administration of activated charcoal be dele-
terious to the patient?
Isbister et al. suggest considering administration of activated 
charcoal in two groups of patients: One group are cooperative 
patients where charcoal may reduce length of hospital stay. 
The other group of patients include those with a life-threate-
ning poisoning that is not easily treated, such as arrhythmias, 
multiorgan failure, where even a small benefit of SDAC may 
improve outcomes and they consider it a duty of care to admi-
nister charcoal.14
Even though activated charcoal has been universally used to 
adsorb a variety of agents and administration of activated char-
coal is considered a low-risk intervention, there are substances 
which are not adsorbed by AC and therefore it should not be 
used to treat these intoxications. These substances are: hydro-
carbons, acids, alkalis, ethanol and heavy metals.1-3,12,14 Lapus 
et al. has used the acronym “PHAILS” to facilitate learning on 
which intoxications AC is not recommended; note that this is 
phonetically similar to the word “Fails”.23 The acronym stands 
for the following: P is for pesticides, petroleum distillates and 
unprotected airway. H is for hydrocarbons, heavy metals and 
time > 1h from ingestion. A is for acids, alkali, alcohols and 
altered level of consciousness with aspiration risk. I is for iron, 
ileus and intestinal obstruction. L stands for lithium and lack of 
gag reflex. Finally, S is for solvents and seizures.23 A description 
of all the contraindications for AC are presented in section 5.
Posology for Single Dose of Activated Charcoal
The optimal dose of activated charcoal is unknown.1 The ad-
sorption can potentially become saturated and therefore with 
greater area available there is potentially more adsorbed subs-
tance.2,10,24 The dose most commonly used is a 1:10 ratio of 
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drug: charcoal.2,12,24
The United States Pharmacopeia (USP DI, 2003) recommended 
the following oral dosage regimen, which is the dosage recom-
mended by the American Academy of Clinical Toxicology: 
• Children up to the first year: 0.5 to 1 g per kg.1 
• Children 1 to 12 years: 0.3 to 1 g per kg.1
• Adolescents and adults: 25 to 100 g, or 1 g per kg. The 
maximum dose is 50g-100g.1,10
Indications for Administration of Multiple Doses of Activated 
Charcoal.
Although the administration of multiple doses of activated 
charcoal has been shown to be beneficial in some cases and 
may enhance the elimination of a variety of drugs.12,25-37 The-
re is no published evidence supporting that administration of 
multiple doses of activated charcoal results in decreased mor-
bidity or mortality in poisoned patients and therefore routine 
administration of multiple doses of activated charcoal is not 
recommended in the poisoned patient. 
By administering more than two doses of activated charcoal 
it is believed that a concentration gradient is maintained in 
the gastrointestinal tract, and thus as drugs continuously pass 
through the intestinal bloodstream, these can potentially be 
absorbed back into the gut and onto the charcoal. This pro-
cess to enhance elimination is known as “gastrointestinal 
dialysis”.12,17,39,40 A summary of the studies performed on AC’s 
enhancement of drug clearance using multiple-dose activated 
charcoal has been performed and published elsewhere and ex-
ceeds the scope of this review.41
Gaudreault12 suggests to consider administration of multiple 
doses of activated charcoal if any of the following criteria are 
met:
1. Intake exceeds the capacity to be adsorbed by a single 
dose.
Adapted from: American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists. 
Position Statement and Practice Guidelines on the Use of Multi-Dose Activated Charcoal in the Treatment of Acute Poisoning. Clin 
Toxicol (Phila). 1999;37(6):731-751. Copyright© 1999, Taylor & Francis.Reprinted with permission from Taylor & Francis.38
Indicated No support or exclude its use Controversial Not recommended
Where elimination was increased.
Studies in Volunteers that demons-
trated  increased elimination.
Studies are insufficient to recom-
mend its use.
Studies have shown no increase in 
elimination.
Carbamazepine Amitriptyline Salicylates Astemizole
Dapsone Dextropropoxyphene Chlorpropamide
Phenobarbital Digitoxin Doxepin
Quinine Digoxin Imipramine
Theophylline Disopyramide Meprobamate
Nadolol Methotrexate
Phenylbutazone Phenytoin
Phenytoin Sodium valproate
Piroxicam Tobramycin
Sotalol Vancomycin
Table 2. Recommendations for Use of Multiple Doses of Activated Charcoal.
2. It can prevent the reabsorption by enterohepatic circula-
tion of the active substance, metabolite, or drug conjuga-
te that is hydrolyzed by bacteria in the bowel.
3. Intoxication by drugs with sustained release.
4. Poisoning by drugs that decrease gastrointestinal transit 
(anticholinergics, tricyclic antidepressants, opioids, and 
phenothiazine). 
The list of toxins on which clearance can potentially be increa-
sed with multiple doses of activated charcoal are described 
in Table 1.12 In the position paper by the American Academy 
of Clinical Toxicology and the European Association of Poisons 
Centres and Clinical Toxicologists the recommendation is that 
administration of multiple doses of activated charcoal should 
be considered in intoxications where there has been a life 
threatening dose of carbamazepine, dapsone, phenobarbital, 
quinine, or theophylline ingested as this could potentially 
avoid the need for invasive extracorporeal techniques needed 
for treatment, but defer the ultimate decision on clinical judge-
ment by the treating physician, presence of contraindications 
and effectiveness of other methods of treatment.38 Their recom-
mendations for use of multiple doses of activated charcoal are 
illustrated in Table 2.38
Posology for Multiple Doses of Activated Charcoal:
More studies are needed to identify the optimal dose for ad-
ministration of multiple doses of activated charcoal.38 The re-
commendation is to administer from 0.25 to 1 g / kg every 
1-4 hours, when there is clinical evidence of absorption of the 
substance either by laboratory tests (increasing serum concen-
tration) or known nature of the substance (sustained release 
formulations).12 Doses of activated charcoal should be conti-
nued until the patient's condition improves by clinical and/or 
laboratory evidence.12 One of the major limitations of multiple 
dosing is increasing nausea or emesis. This could be impro-
ved by administrating lower doses in shorter time intervals or 
continuous administration through a nasogastric tube. In some 
cases its necessary to initiate antiemetics.12,38
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Contraindications
Contraindications to the Use of a Single Dose of Activated Char-
coal
• Use in the setting of intoxication by substances not ad-
sorbed by AC (see section 4.1)
• Substances that have a specific antidote: Administration 
of the antidote should be preferred because concurrent 
administration of activated charcoal with the antidote can 
reduce the effect of the antidote.2,3 
• Non-intact gastrointestinal tract: Patients with anatomic 
or functional abnormalities of the gastrointestinal tract. 
For example, patients with intestinal obstruction.1
• Patient with an unprotected airway or with altered men-
tal status without endotracheal intubation.1,3,11,12 Consider 
that some patients can compromise their airway if the 
toxic agent is a central nervous system depressant.2
• If their use increases the risk of aspiration: For example 
poisoning by a hydrocarbon with high aspiration poten-
tial.1-2,3,11
• Pathologies, recent surgeries or medical conditions that 
increase the risk of gastrointestinal bleeding or perfora-
tion.1-2,3 
• Use on intoxication by corrosive substances. It’s not an ab-
solute contraindication, can be considered if the dose and 
agent ingested can potentially cause systemic toxicity.1,3
Contraindications to the use of multiple doses of activated 
charcoal
The recommendations from the American Academy of Clinical 
Toxicology and the European Association of Poisons Centres 
and Clinical Toxicologists are listed below.38
Absolute contraindications to the use of MDAC are:
• An unconscious patient with an unprotected airway 
• Presence of intestinal obstruction 
•  An injured gastrointestinal tract
Relative contraindications to the use of MDAC are:
• Decreased peristalsis 
Consider that the patient has decreased peristalsis if there 
are decreased bowel sounds, abdominal distention or ileus. 
For example in cases of opioid overdose or anticholinergics. If 
activated charcoal is administered then the physician should 
monitor for gastrointestinal obstruction and prevention of as-
piration.38
Use of Activated Charcoal in the Emergency 
Department
Initial management
When the patient arrives at the emergency room the initial 
resuscitation must be performed immediately. Evaluation of 
the intoxicated patient should start with initial supportive me-
asures and management of the Circulation, Airway, Breathing 
(CAB’s), a history and physical examination, toxidrome recog-
nition, diagnostic testing and then start considering whether 
or not to administer decontamination measures, enhanced eli-
mination measures or antidotes and consult toxicologists or 
regional poison control center. 42,5,43
Subsequently, the physician should assess the risks, consider 
the possible clinical course and potential complications for the 
patient, as well as the risks and benefits of giving therapies 
to prevent absorption, increase elimination or indications for 
antidotes. Therefore, the decision to give a patient activated 
charcoal should be undertaken using the principles of eviden-
ce-based medicine where the clinician should make a value-ba-
sed judgement on each individual patient.14,44 Although there 
is little controlled trial evidence to support the administration 
of activated charcoal, the quantitative studies and evidence in 
small studies of select drugs suggest there is potential benefit 
in some situations and therefore it can have a significant role 
in an individual patient.14,44 
Some authors suggest that the preferred method for gastroin-
testinal decontamination in awake patients with intact airway 
is AC.5 For this process one must consider: the agent, dose, 
time from ingestion, current clinical presentation and indivi-
dual patient factors. This process involves factors specific to 
the physician (experience, knowledge) and the patient (medi-
cal conditions, information provided).3,45 Bailey proposed the 
decontamination triangle as a tool to help clinicians decide 
on administration of AC or not based on the potential toxicity 
of the poison, the benefit of AC, balanced against the risks of 
charcoal.3,22 Activated charcoal or any other method of gastroin-
testinal decontamination should only be considered if there 
has been ingestion of a potentially toxic amount of substance 
that is severe and/or can threaten the patient's life and suppor-
tive management or antidotes may not be sufficient to ensure 
an optimal result. Some authors have recommended against 
use in mild to moderate intoxications.11 
Administration of Activated Charcoal by Nasogastric Tube
The following description for administration of AC was adjusted 
from the “Protocol for Management of the Intoxicated Patient, 
Measures of Gastrointestinal Decontamination: Activated Char-
coal” from the Hospital Universitario del Valle, in Cali, Colom-
bia, written by JBV and Dr. Maurix Rojas, used with permission.
1. Put the patient in a comfortable position, preferably in 
sitting or left lateral position with the head at 45o angle 
and explain the procedure.
2. Isolate the airway with an endotracheal tube in patients 
with altered consciousness.
3. The size of the catheter will depend on the size and 
appearance of the patient: Adults can usually start with a 
16 to 20 Fr catheter.
4. Measure the distance between the earlobe, the nasal apex 
and from there to the xiphoid to estimate the total length 
of the catheter that should be introduced.
5. Quickly and carefully insert the catheter in the nose. Lubri-
cate the catheter with water prior to insertion.
6. Check that the catheter is in the stomach by flushing air 
with a syringe at the proximal end of the catheter and 
simultaneously auscultating on the epigastrium.
7. Secure the catheter to prevent movement during the procedure
8. Perform gastric lavage according to the existing protocol at 
your institution.
9. Prepare a solution of activated charcoal in a ratio of 1 gram 
of activated charcoal per 5 ml of distilled water (1:5).
10. Flush the catheter by administering 20 cc of distilled water 
or saline.
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11. Dispense the total dose of activated charcoal with a 50 cc 
syringe through the catheter quickly.
12. Flush the catheter by administering 20 cc of distilled water 
or saline
13. Remove the nasogastric catheter immediately after the 
procedure.
14. Situate the patient in supine position with the head of bed 
elevated to 45°.
15. Record of the procedure in the medical record.
The clinical use of presentations of activated charcoal in tablets 
or capsules or super-activated charcoal is not recommended.1,10
Complications
Administration of activated charcoal is considered generally 
well tolerated, these are the reported adverse reactions and 
side effects.
• Aspiration: Some cases have been reported where patients 
aspirated gastric contents and the clinical picture has ran-
ged from developing pneumonitis to rapid-onset adult respi-
ratory distress syndrome and death.11,46-48 A randomized cli-
nical trial found equal rate of aspiration pneumonia among 
the group receiving supportive care and those who received 
activated charcoal.20 While another large study of overdose 
patients looking at risk factors for aspiration pneumonitis 
did not identify activated charcoal as a risk factor.46 Therefore 
the true effect is currently unknown. 
• Emesis: Is generally considered an infrequent but the most 
common side effect.20 Reports have ranged from about 7% 
to 15% and even 25% of patients can have emesis although 
the trial by Cooper et al reported no difference in emesis 
when compared to patients who did not receive activated 
charcoal.14,20,49 
• Taste: Ingestion of activated charcoal is reported to be dis-
tasteful to drink which may cause patient dissatisfaction.14
• Gastrointestinal obstruction: Has been reported mainly with 
use of multiple doses of activated charcoal but some studies 
have reported an incidence of 0%.48 In the literature there 
are 9 case reports of intestinal obstruction since 1981.48
• Constipation. More frequently observed with multiple do-
ses.1,38
• Diarrhea.1
• Gastrointestinal perforation: There have been a few cases 
reported with use of multiple dose activated charcoal or after 
nasogastric tube placement.38,50
• Electrolyte disturbances. Mainly related to use of multiple 
doses of activated charcoal. 38 One study found an incidence 
of hypernatremia 1: 176 patients (>155 mEq/L), and hyper-
magnesemia in 1: 292 patients (>3.75 mEq/L).48
• Death: Although very rare, in some case reports have found 
no cause of death from poisoning but activated charcoal.1,38
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